Breakthrough combo therapy trial offers hope for Tough-to-Treat head and neck cancer
Disease control
Recruiting now
This study is testing whether a new two-drug combination (MRG003 plus pucotenlimab) works better than standard chemotherapy for people with advanced nasopharyngeal cancer that has returned or spread. Researchers will enroll 446 patients whose cancer has worsened after at least on…
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC